COVID-19 Oxford Vaccine Update
According to a recent paper published in the renowned scientific
journal, The Lancet, Oxford University Coronavirus vaccine has induced a robust
immune response in phase I/II of the human-based clinical trials. The vaccine is named as ChAdOx1 nCoV-19 and
it is expected to bring in a great potential against COVID-19 pandemic.
Oxford Scientists took the vaccine to clinical trial phases which
included healthy individuals aging from 18 to 55 years with no signs and
symptoms of the COVID-19. Also, they were tested negative against the infection
as well.
Within 1 month, more than 1077 people participated in the trials. Mild
symptoms were observed in the participants who were given the Coronavirus
vaccine. These symptoms included pain, fever, chills, body ache, headache, and restlessness
which were reduced by paracetamol. Yet no serious severe symptoms were
observed. After vaccinating the individuals, safety and tolerance of the vaccine
were ensured by giving paracetamol for the first 24 hours.
How the Vaccine Worked?
The
virus was found to work against the 2 types of immunity in our body:
White Blood Cells
(WBCs) Response
Within the 14 days of vaccination, the proposed vaccine induced a
T Cells or WBCs (which fights infection in our body) response. This response
attacked the cells infected with the Coronavirus.
Antibody* Response
Within 28 days, the antibody response was observed by the vaccine
which involved the production of virus-neutralizing antibodies.
*An antibody is a defensive/protective
molecule produced by our immune system in response to a pathogen.
Booster Dose
After the booster dose, every participant had a detectable
neutralizing antibody against the Coronavirus. According to Professor Andrew
Pollard, Chief investigator of the Oxford Vaccine Trial, among all the
participants, 10 were given two doses of the vaccines. The booster dose showed a
robust immune response and every participant showed a detectable neutralizing
antibody against the Coronavirus. This indicates that the administration of two
doses can be a good vaccination strategy.
Phase 3 Trials
The successful initial results of phase I/II trials lead to a global
clinical program of phase 3 trials. To evaluate the efficacy of the Oxford
vaccine globally, phase 3 trials are already underway in the UK, South Africa
and Brazil.
Large-Scale Production
For the further development, mass production and distribution of the Oxford Coronavirus vaccine, the University of Oxford are working in collaboration with the UK-based global biopharmaceutical company AstraZeneca.
We are one big step closer to the COVID-19 vaccine, so brace yourself & keep following the SOPs. We are very near to finding a cure!
References
Folegatti et al, P. M. (2020). Safety and
immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
preliminary report of a phase 1/2, single-blind, randomized controlled trial. The
Lancet.
(2020). A new study reveals the Oxford coronavirus
vaccine produces strong immune response. UK: The University of Oxford.
Comments
Post a Comment